TRP Supply Chain and Manufacturing Summit on September 23-25, 2025 in Boston, United States

In the high-stakes world of radiopharmaceuticals, the industry is just beginning to realize the full potential of this targeted therapy modality. A surge of capital flowing into the field is signalling not only robust investment, but a shared urgency to strengthen supply pipelines and scale clinical manufacturing capacity.

Alongside this growth, however, the challenge of consistently delivering safe, scalable, and timely radiopharmaceuticals to patients remains.

The 3rd Targeted Radiopharmaceuticals (TRP) Supply Chain and Manufacturing Summit returns to Boston this September to help you strengthen infrastructure, streamline workflows, and future-proof roles in a rapidly evolving and expanding radiopharmaceutical landscape.

Explore how to optimize production capabilities and build a resilient, efficient supply chain by delving into critical topics such as strategic isotope selection, manufacturing scale-up, supplier quality control, regulatory transparency, and last-mile supply networks.

As the only industry-dedicated forum uniting 70+ of the leading C-suite and senior decision-makers in the radiopharmaceutical CMC, regulatory, QC, and supply chain fields, gain exclusive technical and logistical insights from the likes of from AstraZeneca, Novartis, Clarity Pharmaceuticals, Ratio Therapeutics, ImaginAB, and more.

URLs:
Tickets: https://go.evvnt.com/3119139-2?pid=10008
Brochure: https://go.evvnt.com/3119139-3?pid=10008

Time: 8:00 AM - 4:00 PM

Prices:

Drug Developer Full Package (Conference + Pre-Conference Workshop Day): USD 4197.00,

Drug Developer Conference Only: USD 2999.00,

Solution Provider Full Package (Conference + Pre-Conference Workshop Day): USD 5097.00,

Solution Provider Conference Only: USD 3699.00

Speakers: Angel Colina, Director - Cyclotron Engineering and Operations, Columbia University Irving Medical Center, Barbara Lani, Vice President - Quality Affairs, RadioPharm Theranostics, Brett Miller, Senior Director - Global Supply Chain, Telix Pharmaceuticals, Christian Schmidt, Quality Assurance Manager, Ratio Therapeutics, Christopher Adams, Chief Executive Officer, Andarix Pharmaceuticals, Dawn Spiller, Senior Director and Group Manager, AstraZeneca, Geoffrey Johnson, Associate Director- Comprehensive Cancer Center and Nuclear Medicine, Mayo Clinic, Hayley Jackman, Director - CMC Regulatory Affairs, AstraZeneca, Ira Goldman, Nuclear Medicine Industry and Legislative Affairs, Bartlett Hill Enterprises, Jarrod Longcor, Chief Operating Officer, Cellectar Biosciences Inc., Kathleen Brady, Associate Director - Quality Assurance, Imaginab, Kawa Chiu, Chief Technical Officer, Abdera Therapeutics, Lauren Creeden, Head of Clinical, Chemistry Manufacturing and Controls Execution, Clarity Pharmaceuticals, Munir Ghesani, Chief Medical Officer, United Theranostics, Sergio Cerdas, Global Head of Radioligand Therapies and Technical Operations, Novartis AG, Shaemus Gleason, Executive Vice President, Clarity Pharmaceuticals, Shankar Vallabhajosula, VP Radiopharmaceutical Sciences, Convergent Therapeutics, Inc